Release Details

NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences:

H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021

• Presentation Date and Time: On-demand beginning 9/13/2021 at 7:00 AM (ET)
• Webcast: https://journey.ct.events/view/ee8971f7-2bcf-428c-91e5-3ff7d70376ab
• Management will also host 1x1 investor meetings during the conference.
  

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23

• Presentation Date and Time: 9/21/2021 12:25 PM (ET)
• Webcast: https://wsw.com/webcast/oppenheimer16/dcth/2754601
• Management will also host 1x1 investor meetings during the conference. 
  

Cantor Fitzgerald Healthcare Conference: September 27th to 30th, 2021

• Presentation Date and Time: 9/29/2021 4:40 PM (ET)
• Webcast: https://wsw.com/webcast/cantor12/dcth/2065630
• Management will also host 1x1 investor meetings during the conference. 
  

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara 
(646)-755-7412 
james@haydenir.com

Source: Delcath Systems, Inc.